Paterna Biosciences focuses on developing solutions to address male infertility using adult stem cell technology. The company's sole focus is restoring fertility by utilizing the patient's own stem cells to potentially resolve underlying genetic disorders. This work is strictly limited to therapeutic applications for infertility and does not involve heritable trait modification.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SVFounders
Product
Problem
Male infertility is a significant factor in approximately 50% of unsuccessful in vitro fertilization (IVF) cycles, yet therapeutic options remain limited and have not kept pace with advancements in female fertility treatments. Millions of couples worldwide are affected by male infertility, highlighting the need for innovative solutions.
Solution
Paterna Biosciences is developing an in vitro spermatogenesis (IVS) technology designed to generate healthy, optimized sperm from testicular stem cells. This approach aims to address the underlying biological factors contributing to male infertility and improve the success rates of assisted reproductive technologies like IVF. By replicating and driving the development of sperm stem cells in a laboratory setting, Paterna seeks to enhance sperm quality and increase the likelihood of successful and healthy pregnancies. The company's technology represents a potential paradigm shift in male fertility treatment, offering a novel solution for couples struggling to conceive.
Target Audience
The primary target audience includes couples experiencing male factor infertility, fertility clinics offering assisted reproductive technologies, and researchers in the field of reproductive biology.
Features
- In vitro spermatogenesis (IVS) process to cultivate sperm from stem cells.
- Optimization of sperm quality to improve fertilization outcomes.
- Focus on addressing male biological factors contributing to infertility.
- Potential to improve success rates of assisted reproductive technologies (ART) such as IVF.